



## **Synta Pharmaceuticals to Present at the ROTH Capital Partners 21st Annual OC Growth Stock Conference**

February 11, 2009

### **Company to Webcast Presentation on February 17**

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 11, 2009-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Roth Capital OC Growth Stock Conference on Tuesday, February 17 at 4:30 p.m. (PST) at the Ritz-Carlton Laguna Niguel, California.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, [www.syntapharma.com](http://www.syntapharma.com).

### **About Synta Pharmaceuticals**

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which has completed enrollment in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

Source: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.

Rob Kloppenburg, 781-541-7125

or

MacDougall Biomedical Communications

Doug MacDougall, 781-235-3060